Antibody Drug Conjugates Contract Manufacturing Market Report 2026-2036

The global Antibody Drug Conjugates Contract Manufacturing market is projected to grow at a CAGR of 11.4% by 2036

SKU: PHA1398 Category: Drug Discovery Development & Production On-Demand: September 2026Code: PHA1398Pages: 326

← Back to category Drug Discovery Development & Production

Description

Visiongain has published a new report, Antibody Drug Conjugates Contract Manufacturing Market Report 2026-2036. The global ADC contract manufacturing market is valued at US$2.14bn in 2026 and is forecast to reach US$6.31bn by 2036, at a CAGR of 11.4% over the forecast period.

This report provides a comprehensive analysis of the market including market size, growth drivers, competitive positioning, and revenue forecasts across linker, service, condition, and scale of operation segments.

Access a Free Sample of This Report

Download a sample to explore:

Market forecasts and segment breakdowns
Competitive and company-level insights
Key trends shaping the market
Trade, policy, and supply chain analysis

Expanding Clinical and Commercial ADC Pipeline

The continued expansion of the antibody-drug conjugate pipeline is creating sustained demand for specialised contract development and manufacturing services. An ADC programme requires coordinated control of three distinct components – the monoclonal antibody, linker and highly potent payload – followed by conjugation, purification, formulation and analytical characterisation. Manufacturing requirements become more demanding as programmes advance, with late-stage candidates requiring larger GMP batches, validated processes, stability programmes and comprehensive regulatory documentation.

Approved products then create recurring demand for reliable commercial supply and consistent product quality. Many developers do not maintain dedicated high-potency handling and bioconjugation infrastructure internally. This is strengthening demand for specialist providers and integrated CDMOs that can support individual process components or manage an ADC programme across development, clinical supply and commercial manufacturing.

Report Scope and Data Coverage

Global ADC contract manufacturing market analysis
Revenue forecasts to 2036 with annual growth estimates
Segment-level modelling across linker, service, condition, and scale of operation
Regional and national market forecasts across five regions and 14 leading national markets
Competitive intelligence on 20 leading companies

Includes both quantitative forecasting and qualitative strategic analysis covering technology, competition, trade dynamics, and supply chain developments.

Our 300-page report provides 122 tables and 158 charts/graphs.

Segmentation Framework

By Linker

Cleavable Linker
Non-Cleavable Linker

By Service

Process / Cell-line Development
Analytical, Bioassay & QC
CGMP Conjugation & Drug-linker Manufacturing
Fill-finish and Packaging

By Condition

Haematological Malignancies
Solid Tumours
Others

By Scale of Operation

Clinical
Commercial

Geographic Coverage

North America

U.S.
Canada

Europe

Germany
UK
France
Italy
Rest of Europe

Asia Pacific

Japan
China
India
Australia
Rest of Asia Pacific

Latin America

Brazil
Mexico
Rest of Latin America

Middle East and Africa

GCC
South Africa
Rest of MEA

Company Intelligence Coverage

This report includes detailed profiles of 20 leading companies, including:

AbbVie, Inc.
Abzena
AGC Biologics
Ajinomoto Bio-Pharma Services
Axplora
BSP Pharmaceuticals
Cambrex
CARBOGEN AMCIS
Catalent, Inc. (Novo Holdings)
Cerbios-Pharma SA
CordenPharma
Lonza Group AG
Merck KGaA
Oncotec Pharma Produktion GmbH
Piramal Pharma Solutions
Recipharm AB
Samsung Biologics
Sterling Pharma Solutions
Thermo Fisher Scientific Inc. (Patheon Pharma Services)
WuXi XDC

Each profile includes:

Business overview
Financial and market positioning
Technology roadmap and programme wins
Strategic outlook

Key Questions Answered

How is the antibody drug conjugates contract manufacturing market evolving?
What is driving and restraining the market?
How will each submarket segment grow over the forecast period and how much revenue will these submarkets account for in 2036?
How will the market shares for each submarket develop from 2026 to 2036?
Will leading national markets broadly follow macroeconomic dynamics, or will individual markets outperform others?
Who are the leading players and what are their prospects over the forecast period?
How will the industry evolve during the period between 2026 and 2036?

Bespoke Intelligence and Customisation

Visiongain also provides tailored intelligence and advisory support aligned to specific client requirements. This includes:

Custom market segmentation and forecasts
Competitive benchmarking and strategy analysis
Supply chain and sourcing intelligence
High-potency containment and bioconjugation capability assessment
Scenario modelling including tariffs and geopolitical risk

Speak to our team about bespoke requirements

Why This Market Intelligence Matters

The ADC contract manufacturing market is experiencing sustained structural growth as the pipeline expands, commercial approvals accumulate, and pharmaceutical companies increase reliance on specialist CDMOs for high-potency manufacturing, bioconjugation, and integrated development-to-commercial services.

CDMOs with scalable bioconjugation infrastructure, high-potency containment capability, integrated analytical and fill-finish services, and geographically distributed manufacturing networks are best positioned to capture long-term programme value over the next decade.

Access the Full Forecast and Competitive Analysis

Purchase the Antibody Drug Conjugates Contract Manufacturing Market Report 2026-2036 to access the complete dataset, forecasts, and competitive analysis.

Download sample or contact us for enterprise access

For enterprise licensing, customised segmentation or analyst briefings, contact Visiongain directly at contactus@visiongain.com

Government Registration
Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6

1 Report Overview
1.1 Report Overview
1.2 Objectives Of The Study
1.3 Introduction To Antibody Drug Conjugates Contract Manufacturing Market
1.4 What This Report Delivers
1.5 Why You Should Read This Report
1.6 Key Questions Answered By This Analytical Report Include
1.7 Who Is This Report For
1.8 Methodology
1.8.1 Market Definitions
1.8.2 Market Evaluation & Forecasting Methodology
1.8.3 Data Validation
1.8.4 Primary Research
1.8.5 Secondary Research
1.9 Frequently Asked Questions (FAQs)
1.10 Associated Visiongain Reports
1.11 About Visiongain

2 Executive Summary
2.1 Executive Summary
2.2 Market Overview
2.3 Key Findings
2.4 Impact Analysis
2.5 Market Driving Factors
2.6 Market Restraining Factors
2.7 Market Opportunities
2.8 Porter’s Five Forces Analysis
2.8.1 Bargaining Power Of Suppliers
2.8.2 Bargaining Power Of Buyers
2.8.3 Competitive Rivalry
2.8.4 Threat Of Substitutes
2.8.5 Threat Of New Entrants
2.9 PEST Analysis
2.9.1 U.S. Tariffs: What’s The Impact On Global Antibody Drug Conjugates Contract Manufacturing Market?
2.9.1.1 Overview
2.9.1.2 V-Shaped Recovery Scenario
2.9.1.2.1 Why V-Shaped Recovery?
2.9.1.2.2 Impact From Tariffs
2.9.1.2.3 Market Dynamics And Demand Recovery
2.9.1.2.4 Policy And Funding Support
2.9.1.2.5 Timeframe For Recovery
2.9.1.3 U-Shaped Recovery Scenario
2.9.1.3.1 Why U-Shaped Recovery?
2.9.1.3.2 Impact From Tariffs
2.9.1.3.3 Market Dynamics And Demand Recovery
2.9.1.3.4 Policy And Funding Support
2.9.1.3.5 Timeframe For Recovery
2.9.1.4 L-Shaped Recovery Scenario
2.9.1.4.1 Why L-Shaped Recovery?
2.9.1.4.2 Impact From Tariffs
2.9.1.4.3 Market Dynamics And Demand Recovery
2.9.1.4.4 Policy And Funding Support
2.9.1.4.5 Timeframe For Recovery
2.9.2 What Strategic Considerations Should Clients Factor Into Their Near-term (2026-2031) And Long-term (2026-2036) Planning?
2.9.3 Impact Of U.S. And China Trade War On Antibody Drug Conjugates Contract Manufacturing Market
2.9.4 How Might The Most Impacted Countries Experience Positive And Negative Effects Resulting From These Policy Changes?

3 Antibody Drug Conjugates Contract Manufacturing Market Analysis By Linker
3.1 Key Findings
3.2 Linker Segment: Market Attractiveness Index
3.3 Cleavable Linker
3.3.1 Market Forecast By Region, 2026-2036 (US$ Million, AGR %)
3.3.2 Market Share By Region, 2026 & 2036 (%)
3.4 Non-Cleavable Linker
3.4.1 Market Forecast By Region, 2026-2036 (US$ Million, AGR %)
3.4.2 Market Share By Region, 2026 & 2036 (%)

4 Antibody Drug Conjugates Contract Manufacturing Market Analysis By Service
4.1 Key Findings
4.2 Service Segment: Market Attractiveness Index
4.3 Process / Cell-line Development
4.3.1 Market Forecast By Region, 2026-2036 (US$ Million, AGR %)
4.3.2 Market Share By Region, 2026 & 2036 (%)
4.4 Analytical, Bioassay & QC
4.4.1 Market Forecast By Region, 2026-2036 (US$ Million, AGR %)
4.4.2 Market Share By Region, 2026 & 2036 (%)
4.5 CGMP Conjugation & Drug-linker Manufacturing
4.5.1 Market Forecast By Region, 2026-2036 (US$ Million, AGR %)
4.5.2 Market Share By Region, 2026 & 2036 (%)
4.6 Fill-finish And Packaging
4.6.1 Market Forecast By Region, 2026-2036 (US$ Million, AGR %)
4.6.2 Market Share By Region, 2026 & 2036 (%)

5 Antibody Drug Conjugates Contract Manufacturing Market Analysis By Condition
5.1 Key Findings
5.2 Condition Segment: Market Attractiveness Index
5.3 Haematological Malignancies
5.3.1 Market Forecast By Region, 2026-2036 (US$ Million, AGR %)
5.3.2 Market Share By Region, 2026 & 2036 (%)
5.4 Solid Tumours
5.4.1 Market Forecast By Region, 2026-2036 (US$ Million, AGR %)
5.4.2 Market Share By Region, 2026 & 2036 (%)
5.5 Others
5.5.1 Market Forecast By Region, 2026-2036 (US$ Million, AGR %)
5.5.2 Market Share By Region, 2026 & 2036 (%)

6 Antibody Drug Conjugates Contract Manufacturing Market Analysis By Scale Of Operation
6.1 Key Findings
6.2 Scale Of Operation Segment: Market Attractiveness Index
6.3 Clinical
6.3.1 Market Forecast By Region, 2026-2036 (US$ Million, AGR %)
6.3.2 Market Share By Region, 2026 & 2036 (%)
6.4 Commercial
6.4.1 Market Forecast By Region, 2026-2036 (US$ Million, AGR %)
6.4.2 Market Share By Region, 2026 & 2036 (%)

7 Antibody Drug Conjugates Contract Manufacturing Market Analysis By Region
7.1 Key Findings
7.2 Regional Market Size Estimation And Forecast
7.3 North America Antibody Drug Conjugates Contract Manufacturing Market Analysis
7.3.1 Key Findings
7.3.2 North America Antibody Drug Conjugates Contract Manufacturing Market Attractiveness Index
7.3.3 North America Antibody Drug Conjugates Contract Manufacturing Market By Country, 2026, 2031 & 2036 (US$ Million)
7.3.4 North America Antibody Drug Conjugates Contract Manufacturing Market Size Estimation And Forecast By Country
7.3.5 North America Antibody Drug Conjugates Contract Manufacturing Market Size Estimation And Forecast By Linker
7.3.6 North America Antibody Drug Conjugates Contract Manufacturing Market Size Estimation And Forecast By Service
7.3.7 North America Antibody Drug Conjugates Contract Manufacturing Market Size Estimation And Forecast By Condition
7.3.8 North America Antibody Drug Conjugates Contract Manufacturing Market Size Estimation And Forecast By Scale Of Operation
7.4 U.S. Antibody Drug Conjugates Contract Manufacturing Market Analysis
7.5 Canada Antibody Drug Conjugates Contract Manufacturing Market Analysis
7.6 Europe Antibody Drug Conjugates Contract Manufacturing Market Analysis
7.6.1 Key Findings
7.6.2 Europe Antibody Drug Conjugates Contract Manufacturing Market Attractiveness Index
7.6.3 Europe Antibody Drug Conjugates Contract Manufacturing Market By Country, 2026, 2031 & 2036 (US$ Million)
7.6.4 Europe Antibody Drug Conjugates Contract Manufacturing Market Size Estimation And Forecast By Country
7.6.5 Europe Antibody Drug Conjugates Contract Manufacturing Market Size Estimation And Forecast By Linker
7.6.6 Europe Antibody Drug Conjugates Contract Manufacturing Market Size Estimation And Forecast By Service
7.6.7 Europe Antibody Drug Conjugates Contract Manufacturing Market Size Estimation And Forecast By Condition
7.6.8 Europe Antibody Drug Conjugates Contract Manufacturing Market Size Estimation And Forecast By Scale Of Operation
7.7 Germany Antibody Drug Conjugates Contract Manufacturing Market Analysis
7.8 UK Antibody Drug Conjugates Contract Manufacturing Market Analysis
7.9 France Antibody Drug Conjugates Contract Manufacturing Market Analysis
7.10 Italy Antibody Drug Conjugates Contract Manufacturing Market Analysis
7.11 Rest Of Europe Antibody Drug Conjugates Contract Manufacturing Market Analysis
7.12 Asia Pacific Antibody Drug Conjugates Contract Manufacturing Market Analysis
7.12.1 Key Findings
7.12.2 Asia Pacific Antibody Drug Conjugates Contract Manufacturing Market Attractiveness Index
7.12.3 Asia Pacific Antibody Drug Conjugates Contract Manufacturing Market By Country, 2026, 2031 & 2036 (US$ Million)
7.12.4 Asia Pacific Antibody Drug Conjugates Contract Manufacturing Market Size Estimation And Forecast By Country
7.12.5 Asia Pacific Antibody Drug Conjugates Contract Manufacturing Market Size Estimation And Forecast By Linker
7.12.6 Asia Pacific Antibody Drug Conjugates Contract Manufacturing Market Size Estimation And Forecast By Service
7.12.7 Asia Pacific Antibody Drug Conjugates Contract Manufacturing Market Size Estimation And Forecast By Condition
7.12.8 Asia Pacific Antibody Drug Conjugates Contract Manufacturing Market Size Estimation And Forecast By Scale Of Operation
7.13 Japan Antibody Drug Conjugates Contract Manufacturing Market Analysis
7.14 China Antibody Drug Conjugates Contract Manufacturing Market Analysis
7.15 India Antibody Drug Conjugates Contract Manufacturing Market Analysis
7.16 Australia Antibody Drug Conjugates Contract Manufacturing Market Analysis
7.17 Rest Of Asia Pacific Antibody Drug Conjugates Contract Manufacturing Market Analysis
7.18 Latin America Antibody Drug Conjugates Contract Manufacturing Market Analysis
7.18.1 Key Findings
7.18.2 Latin America Antibody Drug Conjugates Contract Manufacturing Market Attractiveness Index
7.18.3 Latin America Antibody Drug Conjugates Contract Manufacturing Market By Country, 2026, 2031 & 2036 (US$ Million)
7.18.4 Latin America Antibody Drug Conjugates Contract Manufacturing Market Size Estimation And Forecast By Country
7.18.5 Latin America Antibody Drug Conjugates Contract Manufacturing Market Size Estimation And Forecast By Linker
7.18.6 Latin America Antibody Drug Conjugates Contract Manufacturing Market Size Estimation And Forecast By Service
7.18.7 Latin America Antibody Drug Conjugates Contract Manufacturing Market Size Estimation And Forecast By Condition
7.18.8 Latin America Antibody Drug Conjugates Contract Manufacturing Market Size Estimation And Forecast By Scale Of Operation
7.19 Brazil Antibody Drug Conjugates Contract Manufacturing Market Analysis
7.20 Mexico Antibody Drug Conjugates Contract Manufacturing Market Analysis
7.21 Rest Of Latin America Antibody Drug Conjugates Contract Manufacturing Market Analysis
7.22 MEA Antibody Drug Conjugates Contract Manufacturing Market Analysis
7.22.1 Key Findings
7.22.2 MEA Antibody Drug Conjugates Contract Manufacturing Market Attractiveness Index
7.22.3 MEA Antibody Drug Conjugates Contract Manufacturing Market By Country, 2026, 2031 & 2036 (US$ Million)
7.22.4 MEA Antibody Drug Conjugates Contract Manufacturing Market Size Estimation And Forecast By Country
7.22.5 MEA Antibody Drug Conjugates Contract Manufacturing Market Size Estimation And Forecast By Linker
7.22.6 MEA Antibody Drug Conjugates Contract Manufacturing Market Size Estimation And Forecast By Service
7.22.7 MEA Antibody Drug Conjugates Contract Manufacturing Market Size Estimation And Forecast By Condition
7.22.8 MEA Antibody Drug Conjugates Contract Manufacturing Market Size Estimation And Forecast By Scale Of Operation
7.23 GCC Antibody Drug Conjugates Contract Manufacturing Market Analysis
7.24 South Africa Antibody Drug Conjugates Contract Manufacturing Market Analysis
7.25 Rest Of MEA Antibody Drug Conjugates Contract Manufacturing Market Analysis

8 Company Profiles
8.1 AbbVie, Inc.
8.1.1 Company Snapshot
8.1.2 Company Overview
8.1.3 Company Financials
8.1.4 Revenue, 2022-2025 (US$ Million)
8.1.5 R&D, 2022-2025 (US$ Million)
8.1.6 Business Segment Market Shares (%), 2025
8.1.7 Geographic Segment Market Shares (%), 2025
8.1.8 Service Benchmarking
8.1.9 Strategic Outlook
8.2 Abzena
8.2.1 Company Snapshot
8.2.2 Company Overview
8.2.3 Company Financials
8.2.4 Revenue, 2022-2025 (US$ Million)
8.2.5 R&D, 2022-2025 (US$ Million)
8.2.6 Business Segment Market Shares (%), 2025
8.2.7 Geographic Segment Market Shares (%), 2025
8.2.8 Service Benchmarking
8.2.9 Strategic Outlook
8.3 AGC Biologics
8.3.1 Company Snapshot
8.3.2 Company Overview
8.3.3 Company Financials
8.3.4 Revenue, 2022-2025 (US$ Million)
8.3.5 R&D, 2022-2025 (US$ Million)
8.3.6 Business Segment Market Shares (%), 2025
8.3.7 Geographic Segment Market Shares (%), 2025
8.3.8 Service Benchmarking
8.3.9 Strategic Outlook
8.4 Ajinomoto Bio-Pharma Services
8.4.1 Company Snapshot
8.4.2 Company Overview
8.4.3 Company Financials
8.4.4 Revenue, 2022-2025 (US$ Million)
8.4.5 R&D, 2022-2025 (US$ Million)
8.4.6 Business Segment Market Shares (%), 2025
8.4.7 Geographic Segment Market Shares (%), 2025
8.4.8 Service Benchmarking
8.4.9 Strategic Outlook
8.5 Axplora
8.5.1 Company Snapshot
8.5.2 Company Overview
8.5.3 Company Financials
8.5.4 Revenue, 2022-2025 (US$ Million)
8.5.5 R&D, 2022-2025 (US$ Million)
8.5.6 Business Segment Market Shares (%), 2025
8.5.7 Geographic Segment Market Shares (%), 2025
8.5.8 Service Benchmarking
8.5.9 Strategic Outlook
8.6 BSP Pharmaceuticals
8.6.1 Company Snapshot
8.6.2 Company Overview
8.6.3 Company Financials
8.6.4 Revenue, 2022-2025 (US$ Million)
8.6.5 R&D, 2022-2025 (US$ Million)
8.6.6 Business Segment Market Shares (%), 2025
8.6.7 Geographic Segment Market Shares (%), 2025
8.6.8 Service Benchmarking
8.6.9 Strategic Outlook
8.7 Cambrex
8.7.1 Company Snapshot
8.7.2 Company Overview
8.7.3 Company Financials
8.7.4 Revenue, 2022-2025 (US$ Million)
8.7.5 R&D, 2022-2025 (US$ Million)
8.7.6 Business Segment Market Shares (%), 2025
8.7.7 Geographic Segment Market Shares (%), 2025
8.7.8 Service Benchmarking
8.7.9 Strategic Outlook
8.8 CARBOGEN AMCIS
8.8.1 Company Snapshot
8.8.2 Company Overview
8.8.3 Company Financials
8.8.4 Revenue, 2022-2025 (US$ Million)
8.8.5 R&D, 2022-2025 (US$ Million)
8.8.6 Business Segment Market Shares (%), 2025
8.8.7 Geographic Segment Market Shares (%), 2025
8.8.8 Service Benchmarking
8.8.9 Strategic Outlook
8.9 Catalent, Inc. (Novo Holdings)
8.9.1 Company Snapshot
8.9.2 Company Overview
8.9.3 Company Financials
8.9.4 Revenue, 2022-2025 (US$ Million)
8.9.5 R&D, 2022-2025 (US$ Million)
8.9.6 Business Segment Market Shares (%), 2025
8.9.7 Geographic Segment Market Shares (%), 2025
8.9.8 Service Benchmarking
8.9.9 Strategic Outlook
8.10 Cerbios-Pharma SA
8.10.1 Company Snapshot
8.10.2 Company Overview
8.10.3 Company Financials
8.10.4 Revenue, 2022-2025 (US$ Million)
8.10.5 R&D, 2022-2025 (US$ Million)
8.10.6 Business Segment Market Shares (%), 2025
8.10.7 Geographic Segment Market Shares (%), 2025
8.10.8 Service Benchmarking
8.10.9 Strategic Outlook
8.11 CordenPharma
8.11.1 Company Snapshot
8.11.2 Company Overview
8.11.3 Company Financials
8.11.4 Revenue, 2022-2025 (US$ Million)
8.11.5 R&D, 2022-2025 (US$ Million)
8.11.6 Business Segment Market Shares (%), 2025
8.11.7 Geographic Segment Market Shares (%), 2025
8.11.8 Service Benchmarking
8.11.9 Strategic Outlook
8.12 Lonza Group AG
8.12.1 Company Snapshot
8.12.2 Company Overview
8.12.3 Company Financials
8.12.4 Revenue, 2022-2025 (US$ Million)
8.12.5 R&D, 2022-2025 (US$ Million)
8.12.6 Business Segment Market Shares (%), 2025
8.12.7 Geographic Segment Market Shares (%), 2025
8.12.8 Service Benchmarking
8.12.9 Strategic Outlook
8.13 Merck KGaA
8.13.1 Company Snapshot
8.13.2 Company Overview
8.13.3 Company Financials
8.13.4 Revenue, 2022-2025 (US$ Million)
8.13.5 R&D, 2022-2025 (US$ Million)
8.13.6 Business Segment Market Shares (%), 2025
8.13.7 Geographic Segment Market Shares (%), 2025
8.13.8 Service Benchmarking
8.13.9 Strategic Outlook
8.14 Oncotec Pharma Produktion GmbH
8.14.1 Company Snapshot
8.14.2 Company Overview
8.14.3 Company Financials
8.14.4 Revenue, 2022-2025 (US$ Million)
8.14.5 R&D, 2022-2025 (US$ Million)
8.14.6 Business Segment Market Shares (%), 2025
8.14.7 Geographic Segment Market Shares (%), 2025
8.14.8 Service Benchmarking
8.14.9 Strategic Outlook
8.15 Piramal Pharma Solutions
8.15.1 Company Snapshot
8.15.2 Company Overview
8.15.3 Company Financials
8.15.4 Revenue, 2022-2025 (US$ Million)
8.15.5 R&D, 2022-2025 (US$ Million)
8.15.6 Business Segment Market Shares (%), 2025
8.15.7 Geographic Segment Market Shares (%), 2025
8.15.8 Service Benchmarking
8.15.9 Strategic Outlook
8.16 Recipharm AB
8.16.1 Company Snapshot
8.16.2 Company Overview
8.16.3 Company Financials
8.16.4 Revenue, 2022-2025 (US$ Million)
8.16.5 R&D, 2022-2025 (US$ Million)
8.16.6 Business Segment Market Shares (%), 2025
8.16.7 Geographic Segment Market Shares (%), 2025
8.16.8 Service Benchmarking
8.16.9 Strategic Outlook
8.17 Samsung Biologics
8.17.1 Company Snapshot
8.17.2 Company Overview
8.17.3 Company Financials
8.17.4 Revenue, 2022-2025 (US$ Million)
8.17.5 R&D, 2022-2025 (US$ Million)
8.17.6 Business Segment Market Shares (%), 2025
8.17.7 Geographic Segment Market Shares (%), 2025
8.17.8 Service Benchmarking
8.17.9 Strategic Outlook
8.18 Sterling Pharma Solutions
8.18.1 Company Snapshot
8.18.2 Company Overview
8.18.3 Company Financials
8.18.4 Revenue, 2022-2025 (US$ Million)
8.18.5 R&D, 2022-2025 (US$ Million)
8.18.6 Business Segment Market Shares (%), 2025
8.18.7 Geographic Segment Market Shares (%), 2025
8.18.8 Service Benchmarking
8.18.9 Strategic Outlook
8.19 Thermo Fisher Scientific Inc. (Patheon Pharma Services)
8.19.1 Company Snapshot
8.19.2 Company Overview
8.19.3 Company Financials
8.19.4 Revenue, 2022-2025 (US$ Million)
8.19.5 R&D, 2022-2025 (US$ Million)
8.19.6 Business Segment Market Shares (%), 2025
8.19.7 Geographic Segment Market Shares (%), 2025
8.19.8 Service Benchmarking
8.19.9 Strategic Outlook
8.20 WuXi XDC
8.20.1 Company Snapshot
8.20.2 Company Overview
8.20.3 Company Financials
8.20.4 Revenue, 2022-2025 (US$ Million)
8.20.5 R&D, 2022-2025 (US$ Million)
8.20.6 Business Segment Market Shares (%), 2025
8.20.7 Geographic Segment Market Shares (%), 2025
8.20.8 Service Benchmarking
8.20.9 Strategic Outlook

9 Conclusion And Recommendations
9.1 Concluding Remarks From Visiongain
9.2 Recommendations For Market Players

10 List Of Tables
10.1 Antibody Drug Conjugates Contract Manufacturing Market Snapshot, 2026 & 2036 (US$ Million, CAGR %)
10.2 Antibody Drug Conjugates Contract Manufacturing Market Forecast By Linker, 2026-2036 (US$ Million, AGR %, CAGR %)
10.3 Cleavable Linker Segment Market Forecast By Region, 2026-2036 (US$ Million, AGR %, CAGR %)
10.4 Non-Cleavable Linker Segment Market Forecast By Region, 2026-2036 (US$ Million, AGR %, CAGR %)
10.5 Antibody Drug Conjugates Contract Manufacturing Market Forecast By Service, 2026-2036 (US$ Million, AGR %, CAGR %)
10.6 Process / Cell-line Development Segment Market Forecast By Region, 2026-2036 (US$ Million, AGR %, CAGR %)
10.7 Analytical, Bioassay & QC Segment Market Forecast By Region, 2026-2036 (US$ Million, AGR %, CAGR %)
10.8 CGMP Conjugation & Drug-linker Manufacturing Segment Market Forecast By Region, 2026-2036 (US$ Million, AGR %, CAGR %)
10.9 Fill-finish And Packaging Segment Market Forecast By Region, 2026-2036 (US$ Million, AGR %, CAGR %)
10.10 Antibody Drug Conjugates Contract Manufacturing Market Forecast By Condition, 2026-2036 (US$ Million, AGR %, CAGR %)
10.11 Haematological Malignancies Segment Market Forecast By Region, 2026-2036 (US$ Million, AGR %, CAGR %)
10.12 Solid Tumours Segment Market Forecast By Region, 2026-2036 (US$ Million, AGR %, CAGR %)
10.13 Others Segment Market Forecast By Region, 2026-2036 (US$ Million, AGR %, CAGR %)
10.14 Antibody Drug Conjugates Contract Manufacturing Market Forecast By Scale Of Operation, 2026-2036 (US$ Million, AGR %, CAGR %)
10.15 Clinical Segment Market Forecast By Region, 2026-2036 (US$ Million, AGR %, CAGR %)
10.16 Commercial Segment Market Forecast By Region, 2026-2036 (US$ Million, AGR %, CAGR %)
10.17 Antibody Drug Conjugates Contract Manufacturing Market Forecast By Region, 2026-2036 (US$ Million, AGR %, CAGR %)
10.18 North America Antibody Drug Conjugates Contract Manufacturing Market Forecast By Country, 2026-2036 (US$ Million, AGR %, CAGR %)
10.19 North America Antibody Drug Conjugates Contract Manufacturing Market Forecast By Linker, 2026-2036 (US$ Million, AGR %, CAGR %)
10.20 North America Antibody Drug Conjugates Contract Manufacturing Market Forecast By Service, 2026-2036 (US$ Million, AGR %, CAGR %)
10.21 North America Antibody Drug Conjugates Contract Manufacturing Market Forecast By Condition, 2026-2036 (US$ Million, AGR %, CAGR %)
10.22 North America Antibody Drug Conjugates Contract Manufacturing Market Forecast By Scale Of Operation, 2026-2036 (US$ Million, AGR %, CAGR %)
10.23 U.S. Antibody Drug Conjugates Contract Manufacturing Market Forecast, 2026-2036 (US$ Million, AGR %, CAGR %)
10.24 Canada Antibody Drug Conjugates Contract Manufacturing Market Forecast, 2026-2036 (US$ Million, AGR %, CAGR %)
10.25 Europe Antibody Drug Conjugates Contract Manufacturing Market Forecast By Country, 2026-2036 (US$ Million, AGR %, CAGR %)
10.26 Europe Antibody Drug Conjugates Contract Manufacturing Market Forecast By Linker, 2026-2036 (US$ Million, AGR %, CAGR %)
10.27 Europe Antibody Drug Conjugates Contract Manufacturing Market Forecast By Service, 2026-2036 (US$ Million, AGR %, CAGR %)
10.28 Europe Antibody Drug Conjugates Contract Manufacturing Market Forecast By Condition, 2026-2036 (US$ Million, AGR %, CAGR %)
10.29 Europe Antibody Drug Conjugates Contract Manufacturing Market Forecast By Scale Of Operation, 2026-2036 (US$ Million, AGR %, CAGR %)
10.30 Germany Antibody Drug Conjugates Contract Manufacturing Market Forecast, 2026-2036 (US$ Million, AGR %, CAGR %)
10.31 UK Antibody Drug Conjugates Contract Manufacturing Market Forecast, 2026-2036 (US$ Million, AGR %, CAGR %)
10.32 France Antibody Drug Conjugates Contract Manufacturing Market Forecast, 2026-2036 (US$ Million, AGR %, CAGR %)
10.33 Italy Antibody Drug Conjugates Contract Manufacturing Market Forecast, 2026-2036 (US$ Million, AGR %, CAGR %)
10.34 Rest Of Europe Antibody Drug Conjugates Contract Manufacturing Market Forecast, 2026-2036 (US$ Million, AGR %, CAGR %)
10.35 Asia Pacific Antibody Drug Conjugates Contract Manufacturing Market Forecast By Country, 2026-2036 (US$ Million, AGR %, CAGR %)
10.36 Asia Pacific Antibody Drug Conjugates Contract Manufacturing Market Forecast By Linker, 2026-2036 (US$ Million, AGR %, CAGR %)
10.37 Asia Pacific Antibody Drug Conjugates Contract Manufacturing Market Forecast By Service, 2026-2036 (US$ Million, AGR %, CAGR %)
10.38 Asia Pacific Antibody Drug Conjugates Contract Manufacturing Market Forecast By Condition, 2026-2036 (US$ Million, AGR %, CAGR %)
10.39 Asia Pacific Antibody Drug Conjugates Contract Manufacturing Market Forecast By Scale Of Operation, 2026-2036 (US$ Million, AGR %, CAGR %)
10.40 Japan Antibody Drug Conjugates Contract Manufacturing Market Forecast, 2026-2036 (US$ Million, AGR %, CAGR %)
10.41 China Antibody Drug Conjugates Contract Manufacturing Market Forecast, 2026-2036 (US$ Million, AGR %, CAGR %)
10.42 India Antibody Drug Conjugates Contract Manufacturing Market Forecast, 2026-2036 (US$ Million, AGR %, CAGR %)
10.43 Australia Antibody Drug Conjugates Contract Manufacturing Market Forecast, 2026-2036 (US$ Million, AGR %, CAGR %)
10.44 Rest Of Asia Pacific Antibody Drug Conjugates Contract Manufacturing Market Forecast, 2026-2036 (US$ Million, AGR %, CAGR %)
10.45 Latin America Antibody Drug Conjugates Contract Manufacturing Market Forecast By Country, 2026-2036 (US$ Million, AGR %, CAGR %)
10.46 Latin America Antibody Drug Conjugates Contract Manufacturing Market Forecast By Linker, 2026-2036 (US$ Million, AGR %, CAGR %)
10.47 Latin America Antibody Drug Conjugates Contract Manufacturing Market Forecast By Service, 2026-2036 (US$ Million, AGR %, CAGR %)
10.48 Latin America Antibody Drug Conjugates Contract Manufacturing Market Forecast By Condition, 2026-2036 (US$ Million, AGR %, CAGR %)
10.49 Latin America Antibody Drug Conjugates Contract Manufacturing Market Forecast By Scale Of Operation, 2026-2036 (US$ Million, AGR %, CAGR %)
10.50 Brazil Antibody Drug Conjugates Contract Manufacturing Market Forecast, 2026-2036 (US$ Million, AGR %, CAGR %)
10.51 Mexico Antibody Drug Conjugates Contract Manufacturing Market Forecast, 2026-2036 (US$ Million, AGR %, CAGR %)
10.52 Argentina Antibody Drug Conjugates Contract Manufacturing Market Forecast, 2026-2036 (US$ Million, AGR %, CAGR %)
10.53 Colombia Antibody Drug Conjugates Contract Manufacturing Market Forecast, 2026-2036 (US$ Million, AGR %, CAGR %)
10.54 Rest Of Latin America Antibody Drug Conjugates Contract Manufacturing Market Forecast, 2026-2036 (US$ Million, AGR %, CAGR %)
10.55 MEA Antibody Drug Conjugates Contract Manufacturing Market Forecast By Country, 2026-2036 (US$ Million, AGR %, CAGR %)
10.56 MEA Antibody Drug Conjugates Contract Manufacturing Market Forecast By Linker, 2026-2036 (US$ Million, AGR %, CAGR %)
10.57 MEA Antibody Drug Conjugates Contract Manufacturing Market Forecast By Service, 2026-2036 (US$ Million, AGR %, CAGR %)
10.58 MEA Antibody Drug Conjugates Contract Manufacturing Market Forecast By Condition, 2026-2036 (US$ Million, AGR %, CAGR %)
10.59 MEA Antibody Drug Conjugates Contract Manufacturing Market Forecast By Scale Of Operation, 2026-2036 (US$ Million, AGR %, CAGR %)
10.60 GCC Antibody Drug Conjugates Contract Manufacturing Market Forecast, 2026-2036 (US$ Million, AGR %, CAGR %)
10.61 South Africa Antibody Drug Conjugates Contract Manufacturing Market Forecast, 2026-2036 (US$ Million, AGR %, CAGR %)
10.62 Rest Of MEA Antibody Drug Conjugates Contract Manufacturing Market Forecast, 2026-2036 (US$ Million, AGR %, CAGR %)
10.63 AbbVie, Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. Of Employees, Company Type, Website, Business Segment)
10.64 AbbVie, Inc.: Service Benchmarking
10.65 AbbVie, Inc.: Strategic Outlook
10.66 Abzena: Key Details, (CEO, HQ, Revenue, Founded, No. Of Employees, Company Type, Website, Business Segment)
10.67 Abzena: Service Benchmarking
10.68 Abzena: Strategic Outlook
10.69 AGC Biologics: Key Details, (CEO, HQ, Revenue, Founded, No. Of Employees, Company Type, Website, Business Segment)
10.70 AGC Biologics: Service Benchmarking
10.71 AGC Biologics: Strategic Outlook
10.72 Ajinomoto Bio-Pharma Services: Key Details, (CEO, HQ, Revenue, Founded, No. Of Employees, Company Type, Website, Business Segment)
10.73 Ajinomoto Bio-Pharma Services: Service Benchmarking
10.74 Ajinomoto Bio-Pharma Services: Strategic Outlook
10.75 Axplora: Key Details, (CEO, HQ, Revenue, Founded, No. Of Employees, Company Type, Website, Business Segment)
10.76 Axplora: Service Benchmarking
10.77 Axplora: Strategic Outlook
10.78 BSP Pharmaceuticals: Key Details, (CEO, HQ, Revenue, Founded, No. Of Employees, Company Type, Website, Business Segment)
10.79 BSP Pharmaceuticals: Service Benchmarking
10.80 BSP Pharmaceuticals: Strategic Outlook
10.81 Cambrex: Key Details, (CEO, HQ, Revenue, Founded, No. Of Employees, Company Type, Website, Business Segment)
10.82 Cambrex: Service Benchmarking
10.83 Cambrex: Strategic Outlook
10.84 CARBOGEN AMCIS: Key Details, (CEO, HQ, Revenue, Founded, No. Of Employees, Company Type, Website, Business Segment)
10.85 CARBOGEN AMCIS: Service Benchmarking
10.86 CARBOGEN AMCIS: Strategic Outlook
10.87 Catalent, Inc. (Novo Holdings): Key Details, (CEO, HQ, Revenue, Founded, No. Of Employees, Company Type, Website, Business Segment)
10.88 Catalent, Inc. (Novo Holdings): Service Benchmarking
10.89 Catalent, Inc. (Novo Holdings): Strategic Outlook
10.90 Cerbios-Pharma SA: Key Details, (CEO, HQ, Revenue, Founded, No. Of Employees, Company Type, Website, Business Segment)
10.91 Cerbios-Pharma SA: Service Benchmarking
10.92 Cerbios-Pharma SA: Strategic Outlook
10.93 CordenPharma: Key Details, (CEO, HQ, Revenue, Founded, No. Of Employees, Company Type, Website, Business Segment)
10.94 CordenPharma: Service Benchmarking
10.95 CordenPharma: Strategic Outlook
10.96 Lonza Group AG: Key Details, (CEO, HQ, Revenue, Founded, No. Of Employees, Company Type, Website, Business Segment)
10.97 Lonza Group AG: Service Benchmarking
10.98 Lonza Group AG: Strategic Outlook
10.99 Merck KGaA: Key Details, (CEO, HQ, Revenue, Founded, No. Of Employees, Company Type, Website, Business Segment)
10.100 Merck KGaA: Service Benchmarking
10.101 Merck KGaA: Strategic Outlook
10.102 Oncotec Pharma Produktion GmbH: Key Details, (CEO, HQ, Revenue, Founded, No. Of Employees, Company Type, Website, Business Segment)
10.103 Oncotec Pharma Produktion GmbH: Service Benchmarking
10.104 Oncotec Pharma Produktion GmbH: Strategic Outlook
10.105 Piramal Pharma Solutions: Key Details, (CEO, HQ, Revenue, Founded, No. Of Employees, Company Type, Website, Business Segment)
10.106 Piramal Pharma Solutions: Service Benchmarking
10.107 Piramal Pharma Solutions: Strategic Outlook
10.108 Recipharm AB: Key Details, (CEO, HQ, Revenue, Founded, No. Of Employees, Company Type, Website, Business Segment)
10.109 Recipharm AB: Service Benchmarking
10.110 Recipharm AB: Strategic Outlook
10.111 Samsung Biologics: Key Details, (CEO, HQ, Revenue, Founded, No. Of Employees, Company Type, Website, Business Segment)
10.112 Samsung Biologics: Service Benchmarking
10.113 Samsung Biologics: Strategic Outlook
10.114 Sterling Pharma Solutions: Key Details, (CEO, HQ, Revenue, Founded, No. Of Employees, Company Type, Website, Business Segment)
10.115 Sterling Pharma Solutions: Service Benchmarking
10.116 Sterling Pharma Solutions: Strategic Outlook
10.117 Thermo Fisher Scientific Inc. (Patheon Pharma Services): Key Details, (CEO, HQ, Revenue, Founded, No. Of Employees, Company Type, Website, Business Segment)
10.118 Thermo Fisher Scientific Inc. (Patheon Pharma Services): Service Benchmarking
10.119 Thermo Fisher Scientific Inc. (Patheon Pharma Services): Strategic Outlook
10.120 WuXi XDC: Key Details, (CEO, HQ, Revenue, Founded, No. Of Employees, Company Type, Website, Business Segment)
10.121 WuXi XDC: Service Benchmarking
10.122 WuXi XDC: Strategic Outlook

11 List Of Figures
11.1 Antibody Drug Conjugates Contract Manufacturing Market Segmentation
11.2 Antibody Drug Conjugates Contract Manufacturing Market By Linker: Market Attractiveness Index
11.3 Antibody Drug Conjugates Contract Manufacturing Market By Service: Market Attractiveness Index
11.4 Antibody Drug Conjugates Contract Manufacturing Market By Condition: Market Attractiveness Index
11.5 Antibody Drug Conjugates Contract Manufacturing Market By Scale Of Operation: Market Attractiveness Index
11.6 Antibody Drug Conjugates Contract Manufacturing Market Attractiveness Index By Region
11.7 Antibody Drug Conjugates Contract Manufacturing Market: Market Dynamics
11.8 Antibody Drug Conjugates Contract Manufacturing Market: Porter’s Five Forces Analysis
11.9 Antibody Drug Conjugates Contract Manufacturing Market: PEST Analysis
11.10 Antibody Drug Conjugates Contract Manufacturing Market Attractiveness Index By Linker
11.11 Antibody Drug Conjugates Contract Manufacturing Market Forecast By Linker, 2026-2036 (US$ Million, AGR %)
11.12 Antibody Drug Conjugates Contract Manufacturing Market Share Forecast By Linker, 2026, 2031, 2036 (%)
11.13 Cleavable Linker Segment Market Forecast By Region, 2026-2036 (US$ Million, AGR %)
11.14 Cleavable Linker Segment Market Share Forecast By Region, 2026 & 2036 (%)
11.15 Non-Cleavable Linker Segment Market Forecast By Region, 2026-2036 (US$ Million, AGR %)
11.16 Non-Cleavable Linker Segment Market Share Forecast By Region, 2026 & 2036 (%)
11.17 Antibody Drug Conjugates Contract Manufacturing Market Attractiveness Index By Service
11.18 Antibody Drug Conjugates Contract Manufacturing Market Forecast By Service, 2026-2036 (US$ Million, AGR %)
11.19 Antibody Drug Conjugates Contract Manufacturing Market Share Forecast By Service, 2026, 2031, 2036 (%)
11.20 Process / Cell-line Development Segment Market Forecast By Region, 2026-2036 (US$ Million, AGR %)
11.21 Process / Cell-line Development Segment Market Share Forecast By Region, 2026 & 2036 (%)
11.22 Analytical, Bioassay & QC Segment Market Forecast By Region, 2026-2036 (US$ Million, AGR %)
11.23 Analytical, Bioassay & QC Segment Market Share Forecast By Region, 2026 & 2036 (%)
11.24 CGMP Conjugation & Drug-linker Manufacturing Segment Market Forecast By Region, 2026-2036 (US$ Million, AGR %)
11.25 CGMP Conjugation & Drug-linker Manufacturing Segment Market Share Forecast By Region, 2026 & 2036 (%)
11.26 Fill-finish And Packaging Segment Market Forecast By Region, 2026-2036 (US$ Million, AGR %)
11.27 Fill-finish And Packaging Segment Market Share Forecast By Region, 2026 & 2036 (%)
11.28 Antibody Drug Conjugates Contract Manufacturing Market Attractiveness Index By Condition
11.29 Antibody Drug Conjugates Contract Manufacturing Market Forecast By Condition, 2026-2036 (US$ Million, AGR %)
11.30 Antibody Drug Conjugates Contract Manufacturing Market Share Forecast By Condition, 2026, 2031, 2036 (%)
11.31 Haematological Malignancies Segment Market Forecast By Region, 2026-2036 (US$ Million, AGR %)
11.32 Haematological Malignancies Segment Market Share Forecast By Region, 2026 & 2036 (%)
11.33 Solid Tumours Segment Market Forecast By Region, 2026-2036 (US$ Million, AGR %)
11.34 Solid Tumours Segment Market Share Forecast By Region, 2026 & 2036 (%)
11.35 Others Segment Market Forecast By Region, 2026-2036 (US$ Million, AGR %)
11.36 Others Segment Market Share Forecast By Region, 2026 & 2036 (%)
11.37 Antibody Drug Conjugates Contract Manufacturing Market Attractiveness Index By Scale Of Operation
11.38 Antibody Drug Conjugates Contract Manufacturing Market Forecast By Scale Of Operation, 2026-2036 (US$ Million, AGR %)
11.39 Antibody Drug Conjugates Contract Manufacturing Market Share Forecast By Scale Of Operation, 2026, 2031, 2036 (%)
11.40 Clinical Segment Market Forecast By Region, 2026-2036 (US$ Million, AGR %)
11.41 Clinical Segment Market Share Forecast By Region, 2026 & 2036 (%)
11.42 Commercial Segment Market Forecast By Region, 2026-2036 (US$ Million, AGR %)
11.43 Commercial Segment Market Share Forecast By Region, 2026 & 2036 (%)
11.44 Antibody Drug Conjugates Contract Manufacturing Market Forecast By Region 2026, 2031, 2036 (Revenue, CAGR%)
11.45 Antibody Drug Conjugates Contract Manufacturing Market Share Forecast By Region 2026, 2031, 2036 (%)
11.46 Antibody Drug Conjugates Contract Manufacturing Market By Region, 2026-2036 (US$ Bn, AGR %)
11.47 North America Antibody Drug Conjugates Contract Manufacturing Market Attractiveness Index
11.48 North America Antibody Drug Conjugates Contract Manufacturing Market By Region, 2026, 2031, 2036 (US$ Million)
11.49 North America Antibody Drug Conjugates Contract Manufacturing Market Forecast By Country, 2026-2036 (US$ Million, AGR %)
11.50 North America Antibody Drug Conjugates Contract Manufacturing Market Forecast By Linker, 2026-2036 (US$ Million, AGR %)
11.51 North America Antibody Drug Conjugates Contract Manufacturing Market Forecast By Service, 2026-2036 (US$ Million, AGR %)
11.52 North America Antibody Drug Conjugates Contract Manufacturing Market Forecast By Condition, 2026-2036 (US$ Million, AGR %)
11.53 North America Antibody Drug Conjugates Contract Manufacturing Market Forecast By Scale Of Operation, 2026-2036 (US$ Million, AGR %)
11.54 U.S. Antibody Drug Conjugates Contract Manufacturing Market Forecast, 2026-2036 (US$ Million, AGR %)
11.55 Canada Antibody Drug Conjugates Contract Manufacturing Market Forecast, 2026-2036 (US$ Million, AGR %)
11.56 Europe Antibody Drug Conjugates Contract Manufacturing Market Attractiveness Index
11.57 Europe Antibody Drug Conjugates Contract Manufacturing Market By Region, 2026, 2031, 2036 (US$ Million)
11.58 Europe Antibody Drug Conjugates Contract Manufacturing Market Forecast By Country, 2026-2036 (US$ Million, AGR %)
11.59 Europe Antibody Drug Conjugates Contract Manufacturing Market Forecast By Linker, 2026-2036 (US$ Million, AGR %)
11.60 Europe Antibody Drug Conjugates Contract Manufacturing Market Forecast By Service, 2026-2036 (US$ Million, AGR %)
11.61 Europe Antibody Drug Conjugates Contract Manufacturing Market Forecast By Condition, 2026-2036 (US$ Million, AGR %)
11.62 Europe Antibody Drug Conjugates Contract Manufacturing Market Forecast By Scale Of Operation, 2026-2036 (US$ Million, AGR %)
11.63 Germany Antibody Drug Conjugates Contract Manufacturing Market Forecast, 2026-2036 (US$ Million, AGR %)
11.64 UK Antibody Drug Conjugates Contract Manufacturing Market Forecast, 2026-2036 (US$ Million, AGR %)
11.65 France Antibody Drug Conjugates Contract Manufacturing Market Forecast, 2026-2036 (US$ Million, AGR %)
11.66 Italy Antibody Drug Conjugates Contract Manufacturing Market Forecast, 2026-2036 (US$ Million, AGR %)
11.67 Rest Of Europe Antibody Drug Conjugates Contract Manufacturing Market Forecast, 2026-2036 (US$ Million, AGR %)
11.68 Asia Pacific Antibody Drug Conjugates Contract Manufacturing Market Attractiveness Index
11.69 Asia Pacific Antibody Drug Conjugates Contract Manufacturing Market By Region, 2026, 2031, 2036 (US$ Million)
11.70 Asia Pacific Antibody Drug Conjugates Contract Manufacturing Market Forecast By Country, 2026-2036 (US$ Million, AGR %)
11.71 Asia Pacific Antibody Drug Conjugates Contract Manufacturing Market Forecast By Linker, 2026-2036 (US$ Million, AGR %)
11.72 Asia Pacific Antibody Drug Conjugates Contract Manufacturing Market Forecast By Service, 2026-2036 (US$ Million, AGR %)
11.73 Asia Pacific Antibody Drug Conjugates Contract Manufacturing Market Forecast By Condition, 2026-2036 (US$ Million, AGR %)
11.74 Asia Pacific Antibody Drug Conjugates Contract Manufacturing Market Forecast By Scale Of Operation, 2026-2036 (US$ Million, AGR %)
11.75 Japan Antibody Drug Conjugates Contract Manufacturing Market Forecast, 2026-2036 (US$ Million, AGR %)
11.76 China Antibody Drug Conjugates Contract Manufacturing Market Forecast, 2026-2036 (US$ Million, AGR %)
11.77 India Antibody Drug Conjugates Contract Manufacturing Market Forecast, 2026-2036 (US$ Million, AGR %)
11.78 Australia Antibody Drug Conjugates Contract Manufacturing Market Forecast, 2026-2036 (US$ Million, AGR %)
11.79 Rest Of Asia Pacific Antibody Drug Conjugates Contract Manufacturing Market Forecast, 2026-2036 (US$ Million, AGR %)
11.80 Latin America Antibody Drug Conjugates Contract Manufacturing Market Attractiveness Index
11.81 Latin America Antibody Drug Conjugates Contract Manufacturing Market By Region, 2026, 2031, 2036 (US$ Million)
11.82 Latin America Antibody Drug Conjugates Contract Manufacturing Market Forecast By Country, 2026-2036 (US$ Million, AGR %)
11.83 Latin America Antibody Drug Conjugates Contract Manufacturing Market Forecast By Linker, 2026-2036 (US$ Million, AGR %)
11.84 Latin America Antibody Drug Conjugates Contract Manufacturing Market Forecast By Service, 2026-2036 (US$ Million, AGR %)
11.85 Latin America Antibody Drug Conjugates Contract Manufacturing Market Forecast By Condition, 2026-2036 (US$ Million, AGR %)
11.86 Latin America Antibody Drug Conjugates Contract Manufacturing Market Forecast By Scale Of Operation, 2026-2036 (US$ Million, AGR %)
11.87 Brazil Antibody Drug Conjugates Contract Manufacturing Market Forecast, 2026-2036 (US$ Million, AGR %)
11.88 Mexico Antibody Drug Conjugates Contract Manufacturing Market Forecast, 2026-2036 (US$ Million, AGR %)
11.89 Rest Of Latin America Antibody Drug Conjugates Contract Manufacturing Market Forecast, 2026-2036 (US$ Million, AGR %)
11.90 MEA Antibody Drug Conjugates Contract Manufacturing Market Attractiveness Index
11.91 MEA Antibody Drug Conjugates Contract Manufacturing Market By Region, 2026, 2031, 2036 (US$ Million)
11.92 MEA Antibody Drug Conjugates Contract Manufacturing Market Forecast By Country, 2026-2036 (US$ Million, AGR %)
11.93 MEA Antibody Drug Conjugates Contract Manufacturing Market Forecast By Linker, 2026-2036 (US$ Million, AGR %)
11.94 MEA Antibody Drug Conjugates Contract Manufacturing Market Forecast By Service, 2026-2036 (US$ Million, AGR %)
11.95 MEA Antibody Drug Conjugates Contract Manufacturing Market Forecast By Condition, 2026-2036 (US$ Million, AGR %)
11.96 GCC Antibody Drug Conjugates Contract Manufacturing Market Forecast, 2026-2036 (US$ Million, AGR %)
11.97 South Africa Antibody Drug Conjugates Contract Manufacturing Market Forecast, 2026-2036 (US$ Million, AGR %)
11.98 Rest Of MEA Antibody Drug Conjugates Contract Manufacturing Market Forecast, 2026-2036 (US$ Million, AGR %)

List of Companies Profiled in the Report
AbbVie, Inc.
Abzena
AGC Biologics
Ajinomoto Bio-Pharma Services
Axplora
BSP Pharmaceuticals
Cambrex
CARBOGEN AMCIS
Catalent, Inc. (Novo Holdings)
Cerbios-Pharma SA
CordenPharma
Lonza Group AG
Merck KGaA
Oncotec Pharma Produktion GmbH
Piramal Pharma Solutions
Recipharm AB
Samsung Biologics
Sterling Pharma Solutions
Thermo Fisher Scientific Inc. (Patheon Pharma Services)
WuXi XDC

List of Other Companies Mentioned in the Report
Almac Group
Anthem Biosciences Limited
Aragen Life Sciences
Cohance Lifesciences Limited
EirGenix, Inc.
Formosa Laboratories, Inc.
FUJIFILM Biotechnologies
GenScript ProBio
Goodwin Biotechnology, Inc.
LOTTE Biologics
MabPlex International
NJ Bio, Inc.
Olon S.p.A.
Syngene International Limited

List of Associations Mentioned in the Report
American Chemical Society (ACS)
Association of the British Pharmaceutical Industry (ABPI)
Association of Biotechnology Led Enterprises (ABLE)
BioProcess Systems Alliance (BPSA)
EuropaBio – The European Association for Bioindustries
International Society of Oncology Pharmacy Practitioners (ISOPP)
Japan Pharmaceutical Manufacturers Association (JPMA)
Korea Biotechnology Industry Organization (KoreaBIO)
Pharmaceutical Research and Manufacturers of America (PhRMA)
Pharmaceutical Supply Chain Initiative (PSCI)
Royal Society of Chemistry (RSC)
Society for Biological Engineering (SBE)
Society for Immunotherapy of Cancer (SITC)
Society of Toxicology (SOT)

Industry Market Reports